{
    "clinical_study": {
        "@rank": "26760", 
        "arm_group": [
            {
                "arm_group_label": "Herceptin IV : Pre-randomization run-in period", 
                "arm_group_type": "Other"
            }, 
            {
                "arm_group_label": "Herceptin SC thigh", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Herceptin SC upper arm", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This open-label, randomized study will evaluate the quality of life, efficacy and safety\n      with subcutaneous Herceptin (trastuzumab) injected either into the thigh or the upper arm in\n      patients with early HER2-positive breast cancer. Patients will receive Herceptin\n      intravenously (8 mg/kg initial dose, followed by 6 mg/kg every 3 weeks) for 6 cycles and a\n      maximum of 6 cycles chemotherapy (neo-adjuvant or adjuvant). Patients will then be\n      randomized to receive in a cross-over design for Cycles 7-10 and 11-14 Herceptin 600 mg\n      subcutaneously every 3 weeks either into the thigh or into the upper arm. For Cycles 15-18\n      patients may choose the injection site for Herceptin. Anticipated time on study treatment is\n      1 year."
        }, 
        "brief_title": "LISAH: A Study of Subcutaneously Administered Herceptin in Patients With HER2-Positive Early Breast Cancer", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female and male patients, >/=18 years of age\n\n          -  HER2-positive early breast cancer\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n\n          -  Hormonal therapy will be allowed as per institutional guidelines\n\n          -  Patients must be Herceptin (trastuzumab) na\u00efve\n\n          -  Left ventricular ejection fraction (LVEF) of >/=55%\n\n          -  Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast\n\n          -  No evidence of residual, locally recurrent or metastatic disease after completion of\n             surgery and chemotherapy, or during concurrent chemotherapy (neo-adjuvant or\n             adjuvant)\n\n          -  Use of concurrent curative radiotherapy will be permitted\n\n        Exclusion Criteria:\n\n          -  History of other malignancy which could affect compliance with the protocol or\n             interpretation of results. Patients with curatively treated carcinoma in situ of the\n             cervix or basal cell carcinoma, and patients with other curatively treated\n             malignancies who have been disease-free for at least 5 years, are eligible\n\n          -  Patients with severe dyspnea at rest or requiring supplementary oxygen therapy\n\n          -  Patients with other concurrent serious diseases that may interfere with planned\n             treatment, including severe pulmonary conditions/illness\n\n          -  Serious cardiac illness or medical conditions that would preclude the use of\n             Herceptin, specifically: history of documented congestive heart failure (CHF),\n             high-risk uncontrolled arrhythmias, angina pectoris requiring medication, clinically\n             significant valvular disease, evidence of transmural infarction on electrocardiogram\n             (ECG), diagnosed poorly controlled hypertension\n\n          -  Pregnant or lactating women\n\n          -  Women of childbearing potential and male patients with partners of childbearing\n             potential who are unable or unwilling to use adequate contraceptive measures during\n             study treatment.\n\n          -  Concurrent enrolment in another clinical trial using an investigational anti-cancer\n             treatment, including hormonal therapy, bisphosphonate therapy and immunotherapy,\n             within 28 days prior to the first dose of study treatment\n\n          -  Known hypersensitivity to trastuzumab, murine proteins, to any of the excipients of\n             Herceptin including hyaluronidase, or a history of severe allergic or immunological\n             reactions, e.g. difficult to control asthma\n\n          -  Inadequate bone marrow, hepatic or renal function"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01928615", 
            "org_study_id": "ML28786", 
            "secondary_id": "2013-001023-39"
        }, 
        "intervention": [
            {
                "arm_group_label": "Herceptin IV : Pre-randomization run-in period", 
                "description": "8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks, 6 cycles", 
                "intervention_name": "trastuzumab [Herceptin]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Herceptin SC thigh", 
                "description": "600 mg subcutaneously into the thigh, Cycles 7-10 or 11-14, (and Cycles 15-18)", 
                "intervention_name": "trastuzumab [Herceptin]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Herceptin SC upper arm", 
                "description": "600 mg subcutaneously every 3 weeks, Cycles 11-14 or 7-10, (and Cycles 15-18)", 
                "intervention_name": "trastuzumab [Herceptin]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Herceptin IV : Pre-randomization run-in period", 
                "description": "Neo-adjuvant or adjuvant chemotherapy, 6 cycles", 
                "intervention_name": "Chemotherapy", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Trastuzumab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Innsbruck", 
                        "country": "Austria", 
                        "zip": "6020"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salzburg", 
                        "country": "Austria", 
                        "zip": "5020"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open Label, Randomised Phase II Study Assessing Quality of Life Associated With Subcutaneous Trastuzumab Injected Into the Thigh or Upper Arm in Patients With HER2-positive Early Breast Cancer", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "Austria: Bundesamt f\u00fcr Sicherheit im Gesundheitswesen (BASG)"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Quality of life: QoL-visual analogue scale", 
            "safety_issue": "No", 
            "time_frame": "Cycles 7-14 (24 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01928615"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 21 days post-dose, Cycles 10 and 14"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "up to 5 years"
            }, 
            {
                "measure": "Disease-free survival", 
                "safety_issue": "No", 
                "time_frame": "up to 5 years"
            }, 
            {
                "measure": "Satisfaction/preference for injection site: HCP/Patient Questionnaires", 
                "safety_issue": "No", 
                "time_frame": "Cycles 7-14 (24 weeks)"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "up to 5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}